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Abstract
Background
Persistent inflammation and immune activation has been hypothesized to contribute to
increased prevalence of subclinical atherosclerosis and cardiovascular disease (CVD) risk
in patients with chronic HIV infection. In this study, we examined the correlation of periph-
eral monocyte subsets and soluble biomarkers of inflammation to coronary artery calcium
(CAC) progression, as measured by cardiac computed tomography scan.
Methods
We conducted a longitudinal analysis utilizing baseline data of 78 participants with HIV
infection on stable antiretroviral therapy (ART) in the Hawaii Aging with HIV-Cardiovascular
study who had available baseline monocyte subset analysis as well as CAC measurement
at baseline and at 2-year follow up. Monocyte phenotypes were assessed from cryopre-
served blood by flow cytometry and plasma was assayed for soluble biomarkers using anti-
body-coated beads in a high sensitivity Milliplex Luminex platform. Change in CAC over 2
years was analyzed as the primary outcome variable.
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Results
Of all monocyte subsets and biomarkers tested, higher non-classical monocyte percent-
age (ρ = 0.259, p = 0.022), interleukin (IL)-6 (ρ = 0.311, p = 0.012), and monocyte chemoat-
tractant protein (MCP)-1 (ρ = 0.524, p = <0.001) were significantly correlated to higher 2-
year CAC progression in unadjusted Spearman’s correlation. Non-classical monocyte per-
centage (ρ = 0.247, p = 0.039), and MCP-1 (ρ = 0.487, p = <0.001), remained significantly
correlated to 2-year CAC progression, while IL-6 was not (ρ = 0.209, p = 0.120) after
adjustment for age, hypertension, diabetes mellitus, total/HDL cholesterol ratio, smoking
history, and BMI.
Conclusion
The percentage of non-classical monocytes and plasma MCP-1 levels were independently
associated with CAC progression and may be related to the progression of atherosclerosis
and increased CVD risk associated with chronic HIV infection on stable ART.
Introduction
Patients with human immunodeficiency virus (HIV) infection, even those with well-sup-
pressed HIV infection on antiretroviral therapy (ART), are at increased risk of cardiovascular
disease (CVD) events [1,2]. Paralleling clinical observation, imaging studies have demonstrated
increased prevalence of subclinical atherosclerosis among HIV-infected patients [3,4]. Inflam-
mation has been increasingly recognized as a key pathologic process in the development and
progression of atherosclerosis [5,6]. As antiretroviral-treated HIV infection remains associated
with persistent immune activation and inflammation, these processes are hypothesized to pro-
mote atherosclerosis and contribute to increased atherosclerotic cardiovascular disease
(ASCVD) risk in HIV-infected patients on ART [7,8]. However, the precise immunologic
mechanisms that promote atherosclerosis in these patients remains uncertain.
Monocytes are one of the key cellular components of the innate immune system involved in
the development and progression of atherosclerotic plaques [6–9]. Monocyte populations are
heterogeneous in nature with differences in the expression of cell surface markers and func-
tional characteristics [9,10]. Currently, monocytes are classified into three subsets on the basis
of their CD14 and CD16 surface expression: “classical” (CD14++CD16-), “intermediate”
(CD14++CD16+) and “non-classical” (CD14low/+CD16++) subsets [11]. This heterogeneity of
monocytes has been implicated in the pathogenesis of atherosclerosis [9,12].
In viremic HIV-infected patients, the expansion of both intermediate and non-classical
monocytes has been reported [13]. However, only the expansion of non-classical monocyte
persisted during 1 year of treatment with ART [13]. A few studies have evaluated the associa-
tion between monocyte subsets and atherosclerosis in HIV-infected patients. Among these
studies, intermediate monocytes [14] and CD16+ monocytes expressing CX3CR1 [15] have
been associated with subclinical atherosclerosis. In addition, our group has observed that a
fourth monocyte subset, termed the “transitional” monocytes, characterized by low levels of
CD14 and negative CD16 expression (CD14dimCD16-) was associated with carotid artery
intima-media thickness (CIMT) [16,17].
Soluble biomarkers are related to several integral processes of atherosclerosis, including
endothelial activation, immune cells recruitment, as well as production of other cytokines and
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acute phase proteins [5,6]. In patients with HIV infection, CRP and IL-6 has been indepen-
dently associated with CVD events in some [18,19] but not all studies [20]. Similarly, indepen-
dent association between monocyte chemoattractant protein (MCP)-1 and subclinical
atherosclerosis in HIV-infected patients has been reported inconsistently [21–25]. Thus, the
relationship between these biomarkers, traditional CVD risk factors, and atherosclerosis
remains uncertain in HIV-infected patients.
In this study, we evaluated the association of monocyte subsets and plasma soluble biomark-
ers with the progression of subclinical atherosclerosis as measured by coronary artery calcium
(CAC) in participants with HIV infection on stable ART. CAC has been demonstrated to cor-
relate with coronary atherosclerotic plaque burden [26] and its progression has been associated
with coronary heart disease (CHD) events [27,28].
Materials and Methods
Study Participants
This is a longitudinal analysis utilizing the baseline data and 2-year follow up data of partici-
pants from the Hawaii Aging with HIV-Cardiovascular (HAHC-CVD) study. In this analysis,
we included only participants who had available baseline monocyte subsets analysis and coro-
nary artery calcium (CAC) measurement at baseline and at 2-year follow up. HAHC-CVD is a
5-year longitudinal cohort study of the role of oxidative stress and inflammation in HIV car-
diovascular risk. The details of the cohort study design and enrollment have been published
previously [29]. Briefly, the study enrolled adults, age 40 years old with documented HIV
infection who were on stable ART for 3 months, from 2009 to 2012. The study was approved
by the Committee on Human Subjects at our institution and was performed in accordance
with the Declaration of Helsinki, all International Conference on Harmonization Good Clinical
Practice guidelines, and applicable local regulatory requirements and laws. Written informed
consents were obtained from all participants.
Clinical assessment
General medical history with special emphasis on CVD and HIV infection was obtained. Clini-
cal parameters including blood pressure (BP), height, weight, body mass index (BMI), and
waist to hip ratio were measured. Smoking was defined as a dichotomous variable of ever
smoked or never smoked. Blood tests, including CD4+ T-cell count, HIV RNA, fasting (noth-
ing by mouth for 12 hours) total, high-density lipoprotein (HDL), directly measured low-den-
sity lipoprotein (LDL) cholesterol, triglycerides, and glucose were performed.
In this study, hypertension was defined as systolic BP 140 mmHg, or diastolic BP 90
mmHg on entry visit, self-reported history of hypertension, or use of anti-hypertensive medi-
cations. Diabetes mellitus was defined by a fasting blood sugar (FBS) 126 mg/dL, 2-hour oral
glucose tolerance test (OGTT) 200 mg/dL, or self-reported history of diabetes mellitus. Ten-
year coronary heart disease (CHD) risk was calculated by Framingham risk score (FRS) based
on a model comprised of age, gender, total cholesterol, HDL cholesterol, systolic blood pres-
sure, treatment of hypertension and any cigarette smoking in the past month using the
National Cholesterol Education Program website (http://hp2010.nhlbihin.net/atpiii/calculator.
asp) [30]. Participants with diabetes (as a CVD equivalent) or clinical CVD (history of myocar-
dial infarction, angina, coronary disease-related cardiac surgery, or ischemic stroke) were auto-
matically classified as having 10-year CHD risk by FRS of 20%. Clinical CVD events were
adjudicated by 2 physician-researchers (C.M.S and D.C.C.). Undetectable plasma HIV RNA
was defined as HIV RNA 50 copies/mL or less.
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Coronary Artery Calcium (CAC) measurements
Computed tomography (CT) examinations for CAC were performed locally in Honolulu,
Hawaii at Accuimaging, a free standing imaging center, using a dual source CT (DSCT) scan-
ner (Siemens 64-slice Somatom) following previously published methods [31]. Technical qual-
ity assurance and centralized imaging analyses were provided by CT reading center at the Los
Angeles Biomedical Research Institute (M. Budoff). A radiologist or cardiologist, who were
blinded to clinical data, quantified CAC using an interactive scoring system to calculate Agat-
ston score, with any Agatston score>0 defining the presence of CAC [32]. All participants
were scanned twice at entry and after 2 years, with total Agatston score used for all analyses.
Cell Staining and Flow Cytometric Analysis
In brief, cryopreserved peripheral blood mononuclear cell (PBMC) were thawed and surface-
stained with the following antibodies to identify monocyte sub populations as previously
described [17]: V500-conjugated anti-CD3, Qdot605-conjugated anti-CD14, Alexa700-conju-
gated anti-CD16, PE-Cy7-conjugated anti-CD56, PE-Cy7-conjugated anti-CD19, PE-Cy7--
conjugated anti-CD20, APC-H7-conjugated HLA-DR monoclonal antibodies (mAbs), All
antibodies were from BD Biosciences, except for Q605-conjugated anti-CD14 and yellow Live/
Dead (Life Technologies). Stained PBMCs were acquired by flow cytometry, using a 4-laser
custom BD-Fortessa instrument (Becton Dickinson) and analyzed with FlowJo software
(Treestar Inc Ashland, OR) as previously described [17] (Fig 1).
The total monocyte count was calculated using white blood cell count (WBC) and percent
monocyte values on the CBC conducted as part of entry evaluations on the same blood speci-
men as that utilized for flow cytometry in line with our previous reports [17].
Soluble biomarkers assessment
Plasma was assayed for soluble biomarkers: soluble E-selectin (sE-selectin), soluble vascular
cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1),
matrix metalloproteinase (MMP)-9, myeloperoxidase (MPO), C-reactive protein (CRP),
serum amyloid A (SAA), serum amyloid P (SAP), IL-1b, IL-6, IL-8, IL-10, tumor necrosis fac-
tor (TNF)-α, MCP-1, vascular endothelial growth factor (VEGF), and interferon (IFN)-γ,
using antibody-coated beads in a high sensitivity Milliplex Human CVD biomarker panel
(Millipore, Billerica, MA) as previously described [23]. The minimum detectable concentration
of CRP of this assay is 0.001 ng/mL. Standard curves and samples were tested in duplicate.
Samples were acquired on a Labscan 200 analyzer (Luminex, Austin, TX) using Bio-Plex man-
ager software (Bio-Rad, Hercules, CA). The coefficients of variation of all biomarker measure-
ments were less than 10%.
Statistical analyses
Demographic, cardiovascular, and HIV-related characteristics as well as monocyte subsets, sol-
uble biomarkers, and CAC measurements were described using the median, first quartile (Q1),
and third quartile (Q3) for continuous variables and frequency and percent for categorical
variables.
Given that 2-year change in CAC is not normally distributed and a substantial percentage
of patients had zero 2-year change in CAC, Spearman’s correlation was conducted to evaluate
baseline characteristics, including demographic, cardiovascular, and HIV-related characteris-
tics, as well as monocytes subsets and soluble biomarkers for their correlation to 2-year change
in CAC.
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To further explore the monocyte subsets and soluble biomarkers that were found to be sig-
nificantly correlated to 2-year change in CAC, we conducted partial Spearman’s correlation
with sequential incremental adjustment for 1) Age, 2) Hypertension, 3) Diabetes mellitus, 4)
Total/HDL cholesterol ratio, 5) Smoking history, and 6) Body mass index (BMI). Adjusted
Spearman’s correlations were conducted using SAS (SAS Institute Inc., Version 9.4, Cary, NC).
All other statistical analyses were conducted using SPSS (IBM, Version 21, Armonk, NY). A
two-sided probability of p-value less than 0.05 was considered statistically significant.
Results
Participant characteristics
Of all participants enrolled into the Hawaii Aging with HIV-Cardiovascular cohort, a total of
78 had available baseline (entry) monocyte subsets analysis as well as coronary artery calcium
(CAC) measurement at baseline (entry) and at 2-year follow up and were included in this anal-
ysis. Soluble biomarkers at baseline were available in 64 of 78 participants included in this anal-
ysis. The demographic, cardiovascular risks, and HIV-related characteristics of the participants
are presented in Table 1. Participants were predominantly white (59%) and male (88.5%), with
median age of 50.5 years. Almost 8% of patients had a history of clinical CVD events. The
median 10-year CHD risk estimated by FRS was 5%. Most participants (84.6%) had undetect-
able HIV RNA and the median CD4+ T-cell count of all participants was 507.5 cells/mm3.
Nucleoside Reverse Transcriptase Inhibitors (NRTI), Non-Nucleoside Reverse Transcriptase
Inhibitors (NNRTI), Protease Inhibitors (PI), and Integrase Inhibitor (II) were used at entry by
98.7%, 47.4%, 50%, and 11.5% of participants respectively. The baseline monocyte subset per-
centage and soluble biomarkers are reported as median (Q1, Q3) in Table 1.
Coronary artery calcium (CAC)
The median (Q1, Q3) CAC Agatston score at baseline was 1.87 (0, 44.75) with 50% of partici-
pants having zero CAC. At 2-year follow up, the median (Q1, Q3) CAC Agatston score was
3.20 (0, 95.41) with 48.7% of participants having zero CAC. The median (Q1, Q3) 2-year CAC
Agatston score progression during 2 years period was 0 (0, 32.715). CAC was increased,
unchanged, and decreased in 46.2%, 47.4%, and 6.4% of participants over 2 years.
Fig 1. Multiparametric flow cytometry phenotype gating strategy to distinguish distinct monocyte
subsets from peripheral blood based on CD16 and CD14 expression. (1) classical monocytes
(CD14++CD16-), (2) intermediate monocytes (CD14++CD16+), (3) non-classical monocytes
(CD14low/+CD16++), including (4) “transitional”monocytes (CD14dimCD16-).
doi:10.1371/journal.pone.0149143.g001
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Table 1. Baseline characteristics, monocyte subset percentage, and soluble biomarkers.
N 78
Age, years [median (Q1, Q3)] 50.50 (46.75, 56.00)
Male gender, n (%) 69 (88.5)
Ethnicity
Caucasian, n (%) 46 (59.0)
African American, n (%) 3 (3.8)
Native Hawaiian/Pacific Islander, n (%) 10 (12.8)
Asian, n (%) 4 (5.1)
Others, n (%) 15 (19.3)
BMI, kg/m2 [median (Q1, Q3)] 26.52 (24.47, 28.88)
Hypertension, n (%) 32 (41.0)
Blood pressure
Systolic Blood Pressure, mmHg [median (Q1, Q3)] 121.50 (113.75, 130.25)
Diastolic Blood Pressure, mmHg [median (Q1, Q3)] 75.00 (69.00, 81.25)
Fasting plasma glucose, mg/dL [median (Q1, Q3)] 90.50 (82.00, 95.25)
Diabetes mellitus, n (%) 7 (9.0)
LDL cholesterol, mg/dL [median (Q1, Q3)] 103.00 (82.00, 122.50)
Total/HDL cholesterol ratio [median (Q1, Q3)] 4.00 (3.38, 5.37)
Smoking history, n (%) 48 (61.5)
10-year CHD risk estimated by Framingham risk score, %
[median (Q1, Q3)]
5 (3, 15.25)
History of clinical CVD events, n (%) 6 (7.7)
Myocardial infarction, n (%) 3 (3.8)
Percutaneous coronary intervention, n (%) 0 (0)
Coronary artery bypass graft, n (%) 1 (1.3)
Stroke, n (%) 2 (2.6)
Current Cardiovascular Medications
ACEI/ARB, n (%) 14 (17.9)
Beta blocker, n (%) 8 (10.3)
Statin, n (%) 17 (21.8)
CD4+ T-cell count, cells/mm3 [median (Q1, Q3)] 507.5 (382, 631.25)
CD4+ T-cell nadir, cells/mm3 [median (Q1, Q3)] a 150 (50, 245)
Undetectable HIV RNA ( 50 copies/mL), n (%) 66 (84.6)
Current Antiretroviral Medications
Nucleoside reverse transcriptase inhibitor, n (%) 77 (98.7)
Non-nucleoside reverse transcriptase inhibitor, n (%) 37 (47.4)
Protease inhibitor, n (%) 39 (50)
Integrase Inhibitor, n (%) 9 (11.5)
Hepatitis C infection, n (%) 13 (16.7)
Soluble biomarkers
sE-Selectin, ng/mL [median (Q1, Q3)] b 33.88 (22.28, 47.97)
sVCAM-1, ng/mL [median (Q1, Q3)] b 1122.54 (877.51, 1302.09)
sICAM-1, ng/mL [median (Q1, Q3)] b 137.54 (112.15, 157.39)
MMP-9, ng/mL [median (Q1, Q3)] b 51.14 (36.23, 81.34)
MPO, ng/mL [median (Q1, Q3)] b 16.04 (11.56, 20.96)
CRP, ng/mL [median (Q1, Q3)] b 8158.20 (3376.22,
30740.73)
SAA, ng/mL [median (Q1, Q3)] 11649.80 (4397.98,
34788.28)
(Continued)
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Correlation of Participant characteristics, Monocyte subsets, and
Soluble biomarkers to 2-year Coronary artery calcium (CAC)
progression
In unadjusted Spearman’s correlation (Table 2), older age (ρ = 0.232, p = 0.041), higher body
mass index (BMI) (ρ = 0.291, p = 0.010), higher 10-year CHD risk estimated by FRS (ρ = 0.264,
p = 0.020), positive history of clinical CVD events (ρ = 0.369, p = 0.001), lower CD4+ T-cell
nadir (ρ = -0.254, p = 0.028), and current protease inhibitor (PI) use (ρ = 0.266, p = 0.019),
were significantly correlated to higher 2-year CAC Agatston score progression.
Higher non-classical monocyte percentage (ρ = 0.259, p = 0.022), IL-6 (ρ = 0.311,
p = 0.012), and MCP-1 (ρ = 0.524, p =<0.001) were significantly correlated to higher 2-year
CAC Agatston score progression in unadjusted Spearman’s correlation (Table 2), while other
monocyte subsets and other soluble biomarkers were not.
The correlations of non-classical monocyte percentage, IL-6, and MCP-1 to 2-year CAC
Agatston score progression were further evaluated in adjusted Spearman’s correlation. After
adjusting for age, hypertension, diabetes mellitus, total/HDL cholesterol ratio, smoking history,
and BMI, non-classical monocyte percentage (ρ = 0.247, p = 0.039), and MCP-1 (ρ = 0.487, p =
<0.001), remained significantly correlated to 2-year CAC Agatston score progression, while
IL-6 was not (ρ = 0.209, p = 0.120) (Table 3). The correlations of non-classical monocyte
Table 1. (Continued)
SAP, ng/mL [median (Q1, Q3)] 70397.25 (47633.43,
126080.25)
IL-1b, pg/mL [median (Q1, Q3)] b 0.305 (0.275, 0.310)
IL-6, pg/mL [median (Q1, Q3)] b 1.67 (1.02, 2.53)
IL-8, pg/mL [median (Q1, Q3)] 3.56 (2.83, 4.52)
IL-10, pg/mL [median (Q1, Q3)] b 2.24 (1.20, 4.68)
TNF-α, pg/mL [median (Q1, Q3)] b 3.17 (1.77, 4.32)
MCP-1, pg/mL [median (Q1, Q3)] b 137.94 (110.56, 168.00)
VEGF, pg/mL [median (Q1, Q3)] b 24.15 (13.79, 50.83)
IFN-γ, pg/mL [median (Q1, Q3)] b 0.78 (0.39, 1.34)
Total monocyte count, cells/L [median (Q1, Q3)] 0.408x109 (0.330 x109,
0.542 x109)
Monocyte subsets
Classical monocytes (CD14++CD16-) percentage [median
(Q1, Q3)]
75.33 (70.04, 80.27)
Intermediate monocytes (CD14++CD16+) percentage
[median (Q1, Q3)]
1.23 (0.52, 3.88)
Non-classical monocytes (CD14low/+CD16++) percentage
[median (Q1, Q3)]
6.15 (4.31, 8.98)
“Transitional” monocytes (CD14dimCD16-) percentage
[median (Q1, Q3)]
15.05 (10.69, 19.74)
a N = 75
b N = 64
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHD, coronary heart disease; CRP, C-reactive protein; CVD,
cardiovascular disease; HDL, high-density lipoprotein; IFN-γ, interferon-γ; IL, interleukin; LDL, low-density lipoprotein; MCP-1, monocyte chemoattractant
protein-1; MMP-9, matrix metalloproteinase-9; MPO, myeloperoxidase; SAA, serum amyloid A; SAP, serum amyloid P; sE-selectin, soluble E-selectin;
sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; TNF-α, tumor necrosis factor-α; VEGF, vascular
endothelial growth factor.
doi:10.1371/journal.pone.0149143.t001
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Table 2. Spearman’s correlation for 2-year coronary artery calcium (CAC) Agatston score progression.
Correlation
Coefficient
p-
value
Age, year 0.232 0.041
Male gender -0.01 0.928
Caucasian ethnicity 0.171 0.133
Body mass index, kg/m2 0.291 0.010
Hypertension 0.202 0.076
Blood pressure
Systolic blood pressure, mmHg 0.163 0.154
Diastolic blood pressure, mmHg -0.005 0.966
Fasting plasma glucose, mg/dL 0.055 0.631
Diabetes mellitus 0.113 0.326
Lipid profile
LDL Cholesterol, mg/dL -0.007 0.950
Total/HDL cholesterol ratio 0.044 0.704
Positive smoking history 0.031 0.791
Positive history of clinical CVD events 0.369 0.001
10-year CHD risk estimated by Framingham risk
score (%)
0.264 0.020
Current Cardiovascular Medications
ACEI/ARB 0.1 0.381
Beta blocker 0.207 0.070
Statin 0.161 0.158
CD4+ T-cell count, cells/mm3 -0.185 0.105
CD4+ T-cell nadir, cells/mm3 a -0.254 0.028
Undetectable HIV RNA ( 50 copies/mL) 0.012 0.919
Current Antiretroviral Medications
Nucleoside reverse transcriptase inhibitor -0.062 0.592
Non-nucleoside reverse transcriptase inhibitor -0.121 0.290
Protease inhibitor 0.266 0.019
Integrase inhibitor 0.08 0.485
Hepatitis C infection -0.012 0.916
Soluble biomarkers
sE-Selectin, ng/mL b -0.128 0.315
sVCAM-1, ng/mL b 0.108 0.397
sICAM-1, ng/mL b 0.034 0.787
MMP-9, ng/mL b 0.091 0.476
MPO, ng/mL b -0.021 0.869
CRP, ng/mL b 0.025 0.842
SAA, ng/mL b 0.089 0.487
SAP, ng/mL b -0.021 0.868
IL-1b, pg/mL b -0.116 0.362
IL-6, pg/mL b 0.311 0.012
IL-8, pg/mL b -0.090 0.479
IL-10, pg/mL b 0.001 0.994
TNF-α, pg/mL b 0.200 0.113
MCP-1, pg/mL b 0.524 <0.001
VEGF, pg/mL b 0.090 0.481
(Continued)
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percentage and MCP-1 to 2-year CAC Agatston score progression were also significant in a
model adjusting for 10-year CHD risk estimated by FRS and BMI instead of each individual
traditional CVD risk factors (data not shown).
Discussion
Persistent inflammation and immune activation have been hypothesized to promote athero-
sclerosis in patients with HIV infection [7,8]. In this cohort of HIV-infected participants on
stable ART, we found that higher baseline percentage of non-classical monocytes and level of
MCP-1, a chemokine that regulates monocytes, were associated with higher 2-year CAC
Table 2. (Continued)
Correlation
Coefficient
p-
value
IFN-γ, pg/mL b 0.020 0.878
Monocyte subsets
Classical monocytes (CD14++CD16-) percentage -0.108 0.348
Intermediate monocytes (CD14++CD16+) percentage 0.127 0.269
Non-classical monocytes (CD14low/+CD16++)
percentage
0.259 0.022
“Transitional” monocytes (CD14dimCD16-) percentage -0.037 0.747
a N = 75
b N = 64
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHD, coronary heart disease; CRP, C-reactive protein; CVD,
cardiovascular disease; HDL, high-density lipoprotein; IFN-γ, interferon-γ; IL, interleukin; LDL, low-density lipoprotein; MCP-1, monocyte chemoattractant
protein-1; MMP-9, matrix metalloproteinase-9; MPO, myeloperoxidase; SAA, serum amyloid A; SAP, serum amyloid P; sE-selectin, soluble E-selectin;
sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; TNF-α, tumor necrosis factor-α; VEGF, vascular
endothelial growth factor.
doi:10.1371/journal.pone.0149143.t002
Table 3. Adjusted Spearman’s correlation for 2-year coronary artery calcium (CAC) Agatston score progression.
Model Note Non-classical monocyte percentage IL-6 a MCP-1 a
M0: Univariate Spearman Rho 0.259 0.311 0.524
p-value 0.022 0.012 <0.001
M1: M0 + Age Partial Rho 0.245 0.289 0.525
p-value 0.032 0.022 <0.001
M2: M1 + Hypertension Partial Rho 0.239 0.278 0.518
p-value 0.038 0.029 <0.001
M3: M2 + Diabetes mellitus Partial Rho 0.239 0.277 0.525
p-value 0.039 0.031 <0.001
M4: M3 + Total/HDL cholesterol ratio Partial Rho 0.222 0.258 0.504
p-value 0.059 0.049 <0.001
M5: M4 + Smoking history Partial Rho 0.249 0.269 0.499
p-value 0.037 0.042 <0.001
M6: M5 + Body mass index Partial Rho 0.247 0.209 0.487
p-value 0.039 0.120 <0.001
a N = 64
HDL, high-density lipoprotein; IL, interleukin; MCP-1, monocyte chemoattractant protein-1.
doi:10.1371/journal.pone.0149143.t003
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progression independent of traditional CVD risk factors. These associations suggest a potential
relation between monocyte-related immune activation and increased CVD risk associated with
HIV infection in these patients.
At the site of atherosclerosis, monocytes adhere to the endothelial surface and migrate into
the subendothelial space in response to chemokines, such as MCP-1 [8,9,33]. In the suben-
dothelial space, they scavenge oxidized lipid particles, transform into foam cells, and secrete
inflammatory cytokines and proteases, such as matrix metalloprotease (MMP), contributing to
the progression of atherosclerosis [8,9]. Non-classical monocytes express high level of adhesion
molecule expression and exhibit a characteristic “patrolling movement” on the endothelial sur-
face [10,34]. They have been proposed to continually survey the endothelium for signs of dam-
age and inflammation [10,34] and have been demonstrated to extravasate rapidly in response
to inflammation in a murine model [35]. It is easy to speculate that these characteristics of
non-classical monocytes may facilitate their recruitment into atherosclerotic lesions. In the
general population, the expansion of non-classical monocytes has been reported in patients
with stable coronary artery disease [36] and non-classical monocyte frequency has been associ-
ated with CIMT in renal transplant recipients [37].
The expansion of the non-classical monocyte subset has been reported in HIV-infected
patients, even after receiving treatment with ART [13]. Given the aforementioned characteris-
tics of non-classical monocytes and their association with CAC progression observed in our
study, it is possible that non-classical monocytes may be actively involved in the pathogenesis
of atherosclerosis in HIV-infected patients. However, it remains inconclusive if they contribute
to progression of atherosclerosis and increased CVD risk in these patients as there is also some
evidence to suggest that they may functionally be atheroprotective, representing a mechanistic
defense against increased ASCVD risk [34].
We did not find any associations between other monocyte subsets and CAC progression in
this study. Intermediate monocyte subset have been reported to be independently associated
with CAC progression in the SUN (Study to Understand the Natural History of HIV/AIDS in
the Era of Effective Therapy) study cohort of HIV-infected patients [14]. We have also previ-
ously reported an independent association between transitional monocyte subset and CIMT in
our entry specimens [16]. The differences observed may be attributable to the limited sample
size of our study, difference between subclinical atherosclerosis assessment by CAC and CIMT,
and the difference in the characteristics of participants in the two studies.
MCP-1 regulates migration of monocytes via its effect on chemokine receptor CCR2 [33]. It
can be produced by several cell types including endothelial cells and monocytes both constitu-
tionally and in response to inflammatory cytokines [33]. Evidence from murine models sup-
ports the role of MCP-1 in attracting monocytes to atherosclerotic lesions [38,39]. The
association between MCP-1 and CAC progression observed in this study is consistent with a
previous report by our group demonstrating a cross-sectional association between MCP-1 and
CAC in our entry specimens [23]. Together, the results of both studies suggest that excess
CVD risk in HIV-infected patients on ART may be related to increased monocyte recruitment
into atherosclerotic plaques. However, the role of MCP-1 in the recruitment of human non-
classical monocytes is unclear at present. In a murine study, the lack of CCR2 receptor did not
significantly affect the distribution of Ly6C- monocytes (equivalent to human non-classical
monocytes) [34].
This study is limited by the small sample size, and the inability of the study to demonstrate
cause and effect due to the observational nature of the study. We also did not assess the poten-
tial impact on ASCVD risk from other infections such as cytomegalovirus (CMV) co-infection,
as well as from translocation of gut microbial products. Host genetics were also not examined
in this study. The duration and prior history of specific antiretroviral medications were not
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extensively analyzed due to the limited number of subjects on each medication. Although PIs
as a class of antiretrovirals were associated with increased CAC, no specific PI was significantly
correlated with CAC. This was also noted for other antiretroviral classes and specific NRTIs,
NNRTIs, and IIs. The lack of a HIV negative comparison group also limited the interpretation
of the soluble biomarkers. The ranges to the biomarkers were broad. We compared our values
to a set of eighty-six HIV negative controls evaluated in different study populations evaluated
by our group and observed that HIV-infected subjects have higher measures of CRP, SAA, and
SAP. Median measures were 6.0% higher in SAP, 57.0% higher in CRP, and 69.3% higher in
SAA compared to the HIV negative group (data unpublished) [40]. This comparison is consis-
tent with a presentation of increased inflammatory tendencies attributable to HIV infection
despite being on stable ART. Despite these limitations, the strength of this study is the careful
clinical characterization and CAC measurement performed in the cohort in association with
detailed monocyte subsets and biomarker assays. The identification of the non-classical mono-
cyte subset and MCP-1 as being related to CAC progression provides potential new therapeutic
targets for intervention in chronic HIV infection.
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